News4 min read
mRNA Melanoma Vaccine Cuts Recurrence Risk 42% in Trial
Merck and Moderna's personalized mRNA therapy, intismeran, cut melanoma recurrence or death by 42% in a Phase 3 trial. What the data show and what's next.
Topic
#Cancer Research
1 story tagged Cancer Research.
Browse sections
- News5 storiesBreaking and trending U.S. news, explained without the noise.
- Tech5 storiesGadgets, AI, apps and the tech stories everyone is searching for.
- Entertainment5 storiesMovies, TV, music, streaming and celebrity news trending in the U.S.
- Sports5 storiesNFL, NBA, MLB, college sports and the moments fans are talking about.
- Money5 storiesPersonal finance, markets, jobs and the economy, in plain English.
- Lifestyle5 storiesHealth, food, travel, home and the trends shaping everyday American life.